特利加压素在老年肝硬化EGVB患者中的真实世界安全性:低钠血症与给药方式
单中心回顾性队列纳入90例≥60岁肝硬化合并EGVB患者,均接受特利加压素联合奥美拉唑。72小时止血成功率98.9%,低钠血症发生率68.9%,Child-Pugh C级和基线血钠降低为独立危险因素;持续泵入组中重度低钠血症数值上低于间断推注组但需前瞻验证。
要点
- 老年肝硬化EGVB患者使用特利加压素需警惕低钠血症,发生率可达68.9%。
- Child-Pugh C级或基线血钠偏低者应加强血钠监测。
- 持续泵入可能减少中重度低钠血症,但证据仅为探索性。
核心结论
- 特利加压素在老年肝硬化EGVB患者中止血效果明确,但低钠血症发生率较高。
- Child-Pugh C级和基线血钠降低是低钠血症的独立危险因素。
- 给药方式对低钠血症的影响需前瞻性研究验证。
研究设计与样本
- 单中心回顾性队列研究,纳入90例≥60岁肝硬化合并EGVB患者。
- 患者于2023年1月1日至2025年12月31日在乐山市中医医院接受特利加压素联合奥美拉唑治疗。
- 采用多因素logistic回归分析低钠血症危险因素,并探索性比较间断推注与持续泵入的安全性差异。
主要发现
- 平均年龄68.5±6.2岁,男性占70.0%,Child-Pugh C级占38.9%。
- 72小时止血成功率98.9%(89/90),5天内再出血率13.5%(12/89),院内死亡率10.0%(9/90)。
- 低钠血症发生率68.9%(62/90),其中中重度(血钠<130 mmol/L)占37.8%(34/90);AKI发生率17.8%(16/90)。
- Child-Pugh C级(OR=3.12,95%CI 1.08-9.02,P=0.03)和基线血钠每降低5 mmol/L(OR=2.05,95%CI 1.21-3.47,P=0.008)为低钠血症独立危险因素。
- 持续泵入组中重度低钠血症发生率数值上低于间断推注组(29.2% vs. 51.5%,名义P=0.04,未校正多重比较),总体低钠血症无显著差异(P=0.19)。
关键数值与推荐
- 老年定义为年龄≥60岁。
- 中重度低钠血症定义为血清钠<130 mmol/L。
临床怎么用
- 对老年肝硬化EGVB患者使用特利加压素时,应常规监测血钠,尤其Child-Pugh C级或基线血钠偏低者。
- 给药方式选择可考虑持续泵入以减少中重度低钠血症风险,但需结合临床谨慎决策。
局限性
- 单中心回顾性设计,样本量小(90例)。
- 给药方式比较为事后探索性分析,非随机分组,结果需谨慎解读。
- 中重度低钠血症的给药方式差异未校正多重比较,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Terlipressin is a first-line vasoactive agent for esophageal and gastric variceal bleeding (EGVB) in patients with liver cirrhosis, typically administered alongside proton pump inhibitors as background acid-suppressive therapy. Despite its widespread use, there is limited real-world safety data concerning its effects on the elderly population. This study aims to assess the real-world safety of terlipressin in elderly EGVB patients, with omeprazole administered as standard background therapy, specifically examining the incidence and risk factors associated with hyponatremia and acute kidney injury (AKI). METHODS: We conducted a single-center retrospective cohort study involving 90 elderly cirrhotic patients (aged ≥60 years) with EGVB. These patients received a combination of terlipressin and omeprazole at Leshan Hospital of Traditional Chinese Medicine between 1 January 2023, and 31 December 2025. The database was finalized on 31 January 2026, with all patients either discharged or deceased, ensuring no loss to follow-up. We collected data on demographic characteristics, liver function reserve, laboratory indicators, efficacy, and safety indicators. To identify risk factors for hyponatremia, we employed multivariate logistic regression analysis. Additionally, we performed an exploratory comparison of safety differences between two administration methods: intermittent intravenous push and continuous pump infusion. This analysis was post hoc and exploratory; given the small sample size and non-random grouping, the findings should be interpreted with caution. RESULTS: The study included 90 patients with an average age of 68.5 ± 6.2 years. Males comprised 70.0% of the cohort, and 38.9% were classified as Child-Pugh class C. The hemostasis success rate within 72 h was 98.9% (89/90), while the rebleeding rate within 5 days was 13.5% (12/89). The in-hospital mortality rate stood at 10.0% (9/90). Hyponatremia occurred in 68.9% (62/90) of patients, with moderate and severe cases (serum sodium <130 mmol/L) accounting for 37.8% (34/90). The incidence of AKI was 17.8% (16/90). Multivariate logistic regression analysis revealed that Child-Pugh class C (OR = 3.12, 95%CI 1.08-9.02, P = 0.03) and reduced baseline serum sodium (per 5 mmol/L decrease, OR = 2.05, 95%CI 1.21-3.47, P = 0.008) were independent risk factors for hyponatremia. Exploratory subgroup analysis showed that the incidence of moderate-to-severe hyponatremia was numerically lower in the continuous pump infusion group than in the intermittent push group (29.2% vs. 51.5%, nominal P = 0.04, uncorrected for multiple comparisons), but there was no significant difference in overall hyponatremia (P = 0.19). Due to the small sample size, this finding requires prospective validation. CONCLUSION: Terlipressin demonstrates a clear hemostatic effect in elderly patients with liver cirrhosis and EGVB when administered with standard background therapy including omeprazole. However, it is associated with a relatively high incidence of hyponatremia. Patients classified as Child-Pugh class C or those with low baseline serum sodium levels require enhanced monitoring of serum sodium. The impact of administration method on hyponatremia requires further investigation.
引用
- Peng Y, Li J, Li M, et al. Real-world safety of terlipressin in elderly patients with liver cirrhosis and esophagogastric variceal bleeding: a focus on hyponatremia and administration methods. Front Pharmacol. 2026. PMID: 42609465. doi:10.3389/fphar.2026.1861406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。